INSMED INC Earnings Per Share (Diluted)
INSMED INC (INSM) reported Earnings Per Share (Diluted) of -$0.06 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- INSMED INC earnings per share, diluted for the quarter ending 2026-06-30 was -$0.06.
- INSMED INC earnings per share, diluted for the quarter ending 2026-03-31 was -$0.76.
- INSMED INC earnings per share, diluted for the quarter ending 2025-12-31 was -$1.54.
- INSMED INC earnings per share, diluted for the quarter ending 2025-09-30 was -$1.75.
- INSMED INC earnings per share, diluted for fiscal 2025 was -$6.42.
- INSMED INC earnings per share, diluted for fiscal 2024 was -$5.57.
- INSMED INC earnings per share, diluted for fiscal 2023 was -$5.34.
- INSMED INC earnings per share, diluted for fiscal 2022 was -$3.91.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.06 10-Q · filed 2026-08-06 | -$0.82 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$0.76 10-Q · filed 2026-05-07 | -$2.29 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$4.03 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$5.70 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$1.54 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$3.28 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$4.98 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$6.42 10-K · filed 2026-02-19 |
| 2025-09-30 | -$1.75 10-Q · filed 2025-10-30 | -$3.45 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$4.89 10-Q · filed 2025-10-30 | -$6.22 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$1.70 10-Q · filed 2026-08-06 | -$3.12 10-Q · filed 2026-08-06 | -$4.44 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$5.72 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$1.42 10-Q · filed 2026-05-07 | -$2.73 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$4.01 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$5.89 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$1.31 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$2.59 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$4.47 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$5.57 10-K · filed 2026-02-19 |
| 2024-09-30 | -$1.27 10-Q · filed 2025-10-30 | -$3.17 derived: net income ÷ weighted average shares · filed 2025-10-30 | -$4.27 10-Q · filed 2025-10-30 | -$5.56 derived: net income ÷ weighted average shares · filed 2026-02-19 |
| 2024-06-30 | -$1.94 10-Q · filed 2025-08-07 | -$3.02 10-Q · filed 2025-08-07 | -$4.31 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$5.43 derived: net income ÷ weighted average shares · filed 2026-02-19 |
| 2024-03-31 | -$1.06 10-Q · filed 2025-05-08 | -$2.34 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$3.45 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$5.21 derived: net income ÷ weighted average shares · filed 2026-02-19 |
| 2023-12-31 | -$1.28 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$2.40 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$4.16 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$5.34 10-K · filed 2026-02-19 |
| 2023-09-30 | -$1.11 10-Q · filed 2024-10-31 | -$2.88 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$4.06 10-Q · filed 2024-10-31 | |
| 2023-06-30 | -$1.78 10-Q · filed 2024-08-08 | -$2.95 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$1.17 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$3.91 10-K · filed 2025-02-20 | |||
| 2022-09-30 | -$1.09 10-Q · filed 2023-10-26 | -$2.68 10-Q · filed 2023-10-26 | ||
| 2022-06-30 | -$0.80 10-Q · filed 2023-08-03 | -$1.60 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | -$0.80 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$3.88 10-K · filed 2024-02-22 | |||
| 2021-09-30 | -$0.96 10-Q · filed 2022-10-27 | -$2.93 10-Q · filed 2022-10-27 | ||
| 2021-06-30 | -$1.07 10-Q · filed 2022-08-04 | -$1.97 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$0.89 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$3.01 10-K · filed 2023-02-23 | |||
| 2020-09-30 | -$0.63 10-Q · filed 2021-10-28 | -$2.00 10-Q · filed 2021-10-28 | ||
| 2020-06-30 | -$0.64 10-Q · filed 2021-08-05 | -$1.38 10-Q · filed 2021-08-05 | ||
| 2019-12-31 | -$3.01 10-K · filed 2022-02-17 | |||
| 2011-12-31 | -$2.95 10-K · filed 2012-03-13 | |||
| 2010-12-31 | -$0.49 10-K · filed 2012-03-13 | |||
| 2009-12-31 | $9.30 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |